Small Fiber Neuropathy Pipeline Report Identifies Multiple Drug Candidates
A new report analyzes over three companies and three potential treatments for small fiber neuropathy. Key players and drugs in development are detailed.
DelveInsight's latest report, "Small Fiber Neuropathy Pipeline Insight 2025," offers a comprehensive overview of the drug development landscape for small fiber neuropathy (SFN).
The report identifies more than three companies actively developing over three distinct therapeutic candidates for SFN. The development pipeline spans both clinical and preclinical stages, with the analysis covering drug development phases, routes of administration, molecule types, and mechanisms of action.
Key companies involved in this space include Vertex Pharmaceuticals and Biogen. Among the potential SFN treatments in development are VX-150 from Vertex Pharmaceuticals and Vixotrigine (BIIB 074) from Biogen. VX-150 acts as a Nav1.8 voltage-gated sodium channel inhibitor and is currently in Phase 2 clinical trials. Vixotrigine is a small molecule that acts centrally and peripherally and is also in Phase 2 studies.
The report further assesses SFN therapies based on product types and development stages, including active and inactive projects. It also examines collaboration agreements and financing details that could impact future market development.
DelveInsight's analysis provides valuable insights into the industry's progress, helping to identify emerging treatment options and understand the current state and future prospects of SFN research.